Statin use and risk of breast cancer

Cancer

Volumn 112, Issue 1, 2008, Pages 27-33

  Pocobelli, Gaia ^a,b   Newcomb, Polly A ^b,c   Trentham Dietz, Amy ^c   Titus Ernstoff, Linda ^d   Hampton, John M ^c   Egan, Kathleen M ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b USA   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

^d NORRIS COTTON CANCER CENTER   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Breast neoplasms; Case control studies; Fluvastatin; Hydroxymethylglutaryl CoA reductase inhibitors; Lovastatin; Pharmacoepidemiology; Pravastatin; Simvastatin

Indexed keywords

FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER REGISTRY; CANCER RISK; DRUG RESPONSE; FEMALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZATION; RISK REDUCTION;

BODY MASS INDEX; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MENOPAUSE; MIDDLE AGED; REPRODUCTIVE HISTORY; RISK FACTORS;

EID: 37449001291     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23129     Document Type: Article

References (36)

1. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA. 1997; 278:313-321.
2. U.S. Department of Health and Human Services Food and Drug Administration. Electronic Orange Book. Approved Drug Products with Therapeutic Equivalence Evaluations. Available at URL: http://www.fda.gov/cder/ob/default. htm; August 2006.
3. Muck AO, Seeger H, Wallwiener D. Inhibitory effect of statins on the proliferation of human breast cancer cells. Int J Clin Pharmacol Ther. 2004;42:695-700.
4. Campbell MJ, Esserman LJ, Zhou Y, et al. Breast cancer growth prevention by statins. Cancer Res. 2006;66:8707-8714.
5. Klement H, Rak J. A disconnect between antitumor and antiangiogenic effects of fluvastatin in vitro and in vivo. Neoplasma. 2006;53:111-118.
6. Newman TB, Hulley SB. Carcinogenicity of lipid-lowenng drugs. JAMA. 1996;275:55-60.
7. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Use of statins and breast cancer: a meta-analysis of 7 randomized clinical trials and 9 observational studies. J Clin Oncol. 2005;23:8606-8612.
8. Kumar AS, Campbell M, Benz CC, Esserman LJ. A call for clinical trials: lipophilic statins may prove effective in treatment and prevention of particular breast cancer subtypes. J Clin Oncol 2006;24:2127, author reply 2127-2128.
9. Prowell TM, Stearns V, Trock B. Lipophilic statins merit additional study for breast cancer chemoprevention. J Clin Oncol 2006;24:2128-2129, author reply 2129.
10. Sprague JR, Wood ME. Statins and breast cancer prevention: time for randomized controlled trials. J Clin Oncol 2006;24:2129-2130, author reply 2130-2121.
11. Katz MS. Therapy insight: potential of statins for cancer chemoprevention and therapy. Nat Clin Pract Oncol. 2005; 2:82-89.
12. Duncan RE, El-Sohemy A, Archer MC. Statins and the risk of cancer. JAMA 2006;295:2720, author reply 2721-2722.
13. Duncan RE, El-Sohemy A, Archer MC. Statins and cancer development. Cancer Epidemiol Biomarkers Prev. 2005;14: 1897-1898.
14. Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci. 1998;19: 26-37.
15. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19:117-125.
16. Cauley JA, McTiernan A, Rodabough RJ, et al. Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst. 2006;98:700-707.
17. Boudreau DM, Gardner JS, Malone KE, Heckbert SR, Blough DK, Daling JR. The association between 3-hydroxy-3-methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. Cancer. 2004;100:2308-2316.
18. Go AS, Lee WY, Yang J, Lo JC, Gurwitz JH. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA. 2006;296:2105-2111.
19. Breslow NE, Day NE. The Analysis of Case-Control Studies. Vol. 1. IARC Scientific Publications No. 32. Lyon: International Agency for Research on Cancer; 1980.
20. Boudreau DM, Yu O, Miglioretti DL, Buist DS, Heckbert SR, Daling JR. Statin use and breast cancer risk in a large population-based setting. Cancer Epidemiol Biomarkers Prev. 2007;16:416-421.
21. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med. 2005;165:2264-2271.
22. Beck P, Wysowski DK, Downey W, Butler-Jones D. Statin use and the risk of breast cancer. J Clin Epidemiol. 2003;56: 280-285.
23. Kaye JA, Meier CR, Walker AM, Jick H. Statin use, hyperlipidaemia, and the risk of breast cancer. Br J Cancer. 2002; 86:1436-1439.
24. Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med. 2000;160:2363-2368.
25. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Shapiro S. Statin use and the risk of breast and prostate cancer. Epidemiology. 2002;13:262-267.
26. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol. 2004;22:2388-2394.
27. Friis S, Poulsen AH, Johnsen SP, et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer. 2005;114:643-647.
28. Cauley JA, Zmuda JM, Lui LY, et al. Lipid-lowering drug use and breast cancer in older women: a prospective study. J Womens Health (Larchmt). 2003;12:749-756.
29. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996; 335:1001-1009.
30. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349-1357.
31. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623-1630.
32. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002; 288:2998-3007.
33. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622.
34. Strandberg TE, Pyorala K, Cook TJ, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet. 2004;364:771-777.
35. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
36. Boudreau DM, Daling JR, Malone KE, Gardner JS, Blough DK, Heckbert SR. A validation study of patient interview data and pharmacy records for antihypertensive, statin, and antidepressant medication use among older women. Am J Epidemiol. 2004;159:308-317.